Fendrick discusses impact of Value-Based Insurance Design on oncology drugs
Share This Page
IHPI member Mark Fendrick recently did an interview with the peer-reviewed journal Clinical Advances in Hematology & Oncology about the impact of Value-Based Insurance Design on oncology drugs.